Ab­b­Vie adds more stel­lar da­ta on ABT-494 — this time for atopic der­mati­tis

ABT-494 has de­liv­ered stel­lar re­sults in a Phase IIb study for atopic der­mati­tis, scor­ing a big win for Ab­b­Vie $AB­BV on a drug it counts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.